Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Rectal Neoplasms 7Colonic Neoplasms 5Pancreatic Neoplasms 3Stomach Neoplasms 2Glioblastoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumor Malignancy 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pediatric Solid Tumors 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Gallbladder Neoplasms 1Colorectal Adenocarcinoma Metastatic to the Liver 1Central Nervous System Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1Astrocytoma 1

Interventions

Gemcitabine 2Capecitabine 2galactomannan 1Sevoflurane 1Phototherapy 1Photochemotherapy 1Pharmacogenomic Testing 1Oxaliplatin 1MK 2206 1Laser Therapy 1Irinotecan 1IMC-001 1Fluorouracil 1Dihematoporphyrin Ether 1Desflurane 1Cisplatin 1Chemotherapy, Adjuvant 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Gallbladder Neoplasms × Irinotecan × Clear all
NCT02720601 2018-01-25

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

New Mexico Cancer Research Alliance

Phase 2 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡